Vibra of Southeastern Michigan LLC

Vibra of Southeastern Michigan LLC was paid $6.35M by Medicaid between Jun 2019 and Mar 2024, across 98 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 51% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	2,220	$82K
2020	23,643	$1.33M
2021	61,781	$2.46M
2022	64,125	$2.23M
2023	9,550	$243K
2024incomplete	176	$8K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	51%	55,568	48,077	$3.24M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	15%	10,437	7,977	$945K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	13%	42,126	37,355	$802K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.9%	11,087	7,961	$245K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.6%	1,906	1,696	$164K
87631		2.3%	1,377	1,348	$146K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.0%	1,503	1,158	$126K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	1.4%	1,301	1,280	$88K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.2%	1,637	1,007	$78K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	487	479	$51K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,877	1,873	$41K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	291	288	$31K

86 more codes

87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,244	$30K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,229	$29K
84443	Thyroid stimulating hormone (TSH)	<1%	1,984	$25K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,010	$24K
87634		<1%	477	$23K
87486		<1%	810	$20K
87581		<1%	811	$20K
80061	Lipid panel	<1%	1,904	$19K
80053	Comprehensive metabolic panel	<1%	2,262	$18K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,938	$18K
82607		<1%	1,329	$14K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,861	$13K
87503		<1%	533	$11K
80074		<1%	290	$10K
82728		<1%	961	$10K
84439		<1%	1,359	$9K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	321	$9K
87498		<1%	356	$8K
84481		<1%	681	$8K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	286	$7K
86769		<1%	177	$6K
87806		<1%	215	$5K
83013		<1%	101	$5K
83540		<1%	800	$4K
86803		<1%	334	$4K
82746		<1%	296	$3K
83550		<1%	434	$3K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	116	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	369	$2K
84153		<1%	147	$2K
85046		<1%	410	$2K
84460		<1%	394	$2K
84450		<1%	391	$2K
86003		<1%	15	$2K
83735		<1%	291	$1K
86696		<1%	107	$1K
85027		<1%	286	$1K
86140		<1%	272	$1K
81001		<1%	472	$1K
86695		<1%	105	$960.81
84550		<1%	221	$765.96
83001		<1%	51	$750.30
87563		<1%	35	$738.58
86704		<1%	77	$705.95
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	15	$637.20
86703		<1%	60	$592.21
86038		<1%	61	$566.84
86592		<1%	181	$560.51
83002		<1%	38	$559.98
82043		<1%	125	$543.98
86708		<1%	58	$541.79
84100		<1%	146	$532.49
86706		<1%	62	$506.38
83655		<1%	50	$501.50
82248		<1%	122	$501.38
85651		<1%	162	$497.94
82565		<1%	95	$401.48
84403		<1%	18	$362.67
80048	Basic metabolic panel (calcium, ionized)	<1%	51	$354.80
84702		<1%	29	$334.46
87640		<1%	13	$316.46
87653		<1%	13	$316.46
84520		<1%	95	$310.82
82247		<1%	73	$303.68
82570		<1%	75	$298.94
86850		<1%	32	$258.88
87088		<1%	34	$227.36
84075		<1%	52	$220.79
82784		<1%	24	$200.20
83615		<1%	37	$185.00
86431		<1%	41	$181.09
82550		<1%	30	$152.05
81003		<1%	81	$149.60
85652		<1%	61	$136.64
87077		<1%	17	$120.19
36415	Collection of venous blood by venipuncture	<1%	1,016	$110.62
87186		<1%	16	$106.81
86005		<1%	12	$101.40
86901		<1%	33	$81.51
86900		<1%	33	$81.51
80076		<1%	13	$81.12
87081		<1%	12	$54.04
82465		<1%	12	$43.32
85610		<1%	12	$42.32
84436		<1%	13	$34.14
84156		<1%	13	$33.20

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHOLLINGER, BRAD (PRESIDENT)

Same official

Other billing entities under HOLLINGER, BRAD

Full network →

Provider	Location	Paid
Vibra Hospital of San Bernardino, LLC	San Bernardino, CA	$31.29M
7173 North Sharon Avenue Operating Company, LLC	Fresno, CA	$971K
1300 Campbell Lane Operating Company LLC	Bowling Green, KY	$224K
Vibra Rehabilitation Hospital of Florence LLC	Florence, KY	$66K
4499 Acushnet Avenue Operating Company, LLC	New Bedford, MA	$3K
Vibra Rehabilitation Hospital of Southern Indiana, LLC	New Albany, IN	$3K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.